Epstein–Barr virus associated post-transplantation lymphoproliferative disorder with hemophagocytosis in a child with Wiskott–Aldrich syndrome
Article first published online: 16 NOV 2004
Copyright © 2004 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 45, Issue 3, pages 340–343, September 2005
How to Cite
Wang, I. J., Lu, M. Y., Chiang, B. L., Lin, W. C., Lin, D. T. and Lin, K.-H. (2005), Epstein–Barr virus associated post-transplantation lymphoproliferative disorder with hemophagocytosis in a child with Wiskott–Aldrich syndrome. Pediatr. Blood Cancer, 45: 340–343. doi: 10.1002/pbc.20191
- Issue published online: 13 JUL 2005
- Article first published online: 16 NOV 2004
- Manuscript Accepted: 14 JUL 2004
- Manuscript Received: 5 JAN 2004
- Epstein–Barr virus;
- post-transplantation lymphoproliferative disorder;
- virus-associated hemophagocytosis syndrome;
- Wiskott–Aldrich syndrome
A 23-month-old boy with Wiskott–Aldrich syndrome (WAS) received human leukocyte antigen (HLA)-one locus mismatched, unmanipulated allogeneic bone marrow graft from his mother. An Epstein–Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder (PTLD) of donor cell origin and hemophagocytosis syndrome with fever, lymphadenopathy, hepatosplenomegaly, seizures, involuntary movements and pancytopenia developed 52 days after transplantation. It was difficult to decide on the treatment strategy because the patient presented with B-cell hyperplasia that morphologically appeared malignant but was oligoclonal by heavy-chain analyses. Despite of donor leukocyte transfusion, low dose chemotherapy, and anti-B cell monoclonal antibody immunotherapy, the patient died 107 days after transplantation. © 2004 Wiley-Liss, Inc.